ARS Pharmaceuticals Q2 EPS $(0.18) Misses $(0.17) Estimate, Sales $10.00K
Portfolio Pulse from Benzinga Newsdesk
ARS Pharmaceuticals (NASDAQ:SPRY) reported Q2 losses of $(0.18) per share, missing the analyst consensus estimate of $(0.17) by 5.88 percent. The company reported $10.00 thousand in sales this quarter.
August 10, 2023 | 8:36 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
ARS Pharmaceuticals reported Q2 losses greater than analyst estimates. This could negatively impact the stock in the short term.
ARS Pharmaceuticals reported a higher loss per share than what analysts had estimated. This indicates that the company's financial performance was worse than expected, which could lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100